Durable Responses in Fit Elderly Patients with Chronic Lymphocytic Leukemia (CLL) in a Randomised, Fludarabine-Based, Immunochemotherapy Dose De-Escalation Study - Long-Term Follow-up By Treatment Arm and Mutational Status
Stephen P. Mulligan(Royal North Shore Hospital), Bryone J. Kuss(Flinders Medical Centre), Rosemary Harrup(University of Tasmania), Devinder Gill(Princess Alexandra Hospital), Constantine S. Tam(The Alfred Hospital), Gavin Cull(Sir Charles Gairdner Hospital), Naomi Mackinlay(Royal North Shore Hospital), Leanne Berkahn(Auckland City Hospital), Philip Campbell(Barwon Health), Xavier C. Badoux(St George Hospital), David Simpson(North Shore Hospital), Giles Best(Flinders University)
Cited by 0
Related Papers
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
|American Journal of Hematology|2019|472
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
|The Lancet|2021|456
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2022|453